Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Rating of “Reduce” by Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been given an average recommendation of “Reduce” by the eight analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $24.50.

A number of brokerages have recently weighed in on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Finally, Barclays cut their target price on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. New York State Common Retirement Fund lifted its position in Amphastar Pharmaceuticals by 86.4% during the 3rd quarter. New York State Common Retirement Fund now owns 90,169 shares of the company’s stock valued at $2,403,000 after acquiring an additional 41,800 shares during the period. SG Americas Securities LLC purchased a new position in Amphastar Pharmaceuticals during the 4th quarter valued at about $2,504,000. Clark Capital Management Group Inc. purchased a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at about $7,560,000. SummerHaven Investment Management LLC purchased a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at about $1,018,000. Finally, Denali Advisors LLC lifted its position in Amphastar Pharmaceuticals by 56.9% during the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after acquiring an additional 76,765 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Trading Up 1.5%

Shares of AMPH opened at $19.10 on Thursday. The firm’s 50-day moving average price is $20.11 and its 200-day moving average price is $23.93. The firm has a market capitalization of $842.12 million, a price-to-earnings ratio of 11.51, a PEG ratio of 3.05 and a beta of 0.97. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals has a 1-year low of $16.65 and a 1-year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million for the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. Sell-side analysts anticipate that Amphastar Pharmaceuticals will post 2.93 EPS for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.